International Extranodal NK/T-cell Lymphoma Project
NCT02386813 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 770
Last updated 2017-04-11
Summary
This study is to explore risk factors for poor progression-free survival (PFS) and overall survival (OS) in ENKTL, and establish a prognostic model for ENKTL patients treated with non-anthracycline based treatment.
Conditions
- Extranodal NK/T-cell Lymphoma, Nasal Type
Sponsors & Collaborators
-
Seok Jin Kim
collaborator UNKNOWN -
Consortium for Improving Survival of Lymphoma
collaborator OTHER -
Asia Lymphoma Study Group
collaborator UNKNOWN -
Lymphoma Study Association
collaborator OTHER -
Dok Hyun Yoon
collaborator UNKNOWN -
Arnaud Jaccard
collaborator UNKNOWN -
Wee Joo Chng
collaborator UNKNOWN -
Soon Thye Lim
collaborator UNKNOWN -
Huangming Hong
collaborator UNKNOWN -
Yong Park
collaborator UNKNOWN -
Kian Meng Chang
collaborator UNKNOWN -
Yoshinobu Maeda
collaborator UNKNOWN -
Fumihiro Ishida
collaborator UNKNOWN -
Dong-Yeop Shin
collaborator UNKNOWN -
Jin Seok Kim
collaborator UNKNOWN -
Seong Hyun Jeong
collaborator UNKNOWN -
Deok-Hwan Yang
collaborator UNKNOWN -
Jae-Cheol Jo
collaborator UNKNOWN -
Gyeong-Won Lee
collaborator UNKNOWN -
Chul Won Choi
collaborator UNKNOWN -
Won-Sik Lee
collaborator UNKNOWN -
Tsai-Yun Chen
collaborator UNKNOWN -
Kiyeun Kim
collaborator UNKNOWN -
Sin-Ho Jung
collaborator UNKNOWN -
Tohru Murayama
collaborator UNKNOWN -
Yasuhiro Oki
collaborator UNKNOWN -
Ranjana Advani
collaborator UNKNOWN -
Francesco d'Amore
collaborator UNKNOWN -
Norbert Schmitz
collaborator UNKNOWN -
Cheolwon Suh
collaborator UNKNOWN -
Ritsuro Suzuki
collaborator UNKNOWN -
Yok Lam Kwong
collaborator UNKNOWN -
Tong-Yu Lin
collaborator UNKNOWN -
Samsung Medical Center
lead OTHER
Principal Investigators
-
Won Seog Kim, MD, PhD · Samsung Medical Center
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2013-01-31
- Primary Completion
- 2015-06-30
- Completion
- 2015-06-30
Countries
- South Korea
Study Locations
More Related Trials
-
A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type
NCT04414163 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Natural Killer Cells Function in Patients With Chronic Lymphocytic Leukemia
NCT00934986 ·Status: COMPLETED ·Phase: NA
-
T-Cell Project: Prospective Collection of Data in Patients With Peripheral T-Cell Lymphoma
NCT01142674 ·Status: COMPLETED
-
Immunotherapy in Lymphoma
NCT06796517 ·Status: RECRUITING
-
Prospective Observational International Registry of Patients With Newly Diagnosed Peripheral T Cell Lymphoma.
NCT03964480 ·Status: RECRUITING
-
Study of the Biological Mechanisms Associated With the Immunogenicity in Anaplastic Large Cell Lymphoma ( ALCL ) ALK +
NCT02902874 ·Status: COMPLETED ·Phase: NA
-
Gemcitabine in NK/T Cell Lymphoma
NCT01660568 ·Status: COMPLETED
-
Study of MK 2206 in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma
NCT01466868 ·Status: TERMINATED ·Phase: PHASE2
-
A Retrospective Study on Extranodal DLBCL
NCT06549361 ·Status: COMPLETED
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of YK012
NCT06565689 ·Status: RECRUITING ·Phase: PHASE1
-
Compare Efficacy of CHOP Versus Fractionated ICED in Transplant-eligible Patients With Previously Untreated PTCL
NCT02445404 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer
NCT06139406 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Circulating Tumor DNA Sequencing in Patients With Peripheral T-cell Lymphomas
NCT06089941 ·Status: ACTIVE_NOT_RECRUITING
-
Allogeneic γδ T Cells Immunotherapy in r/r Non-Hodgkin's Lymphoma (NHL) or Peripheral T Cell Lymphomas (PTCL) Patients
NCT04696705 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Safety, Tolerability, and Efficacy of AT101 in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
NCT05338931 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Clinical Study of the Value of Circulating Free Methylated EBV DNA in Extranodal NK/T Cell Lymphoma
NCT05343377 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
A Retrospective Study of Clinical, Phenotypic and Genetic Factors of Peripheral T-Cell Lymphomas
NCT02788916 ·Status: COMPLETED
-
A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy
NCT01232556 ·Status: TERMINATED ·Phase: PHASE3
-
A Study of Improving the Efficacy of Treatment in High Risk T Cell Lymphoma Patients
NCT01788137 ·Status: UNKNOWN ·Phase: PHASE3
-
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
NCT05131022 ·Status: RECRUITING ·Phase: PHASE1
-
Chemotherapy Plus PD-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T-cell Lymphoma.
NCT05821192 ·Status: UNKNOWN ·Phase: NA
-
Clinical Study of Liposomal Mitoxantrone Hydrochloride Injection Combined With Pegaspargase in the Treatment of NKTCL
NCT04509466 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Prospective Analysis of Circulating Nucleosomes in Patients Receiving a First Line Treatment for a Non-Hodgkin Lymphoma
NCT06813573 ·Status: RECRUITING ·Phase: NA
-
Relapsed or Refractory Primary Diffuse Large B-cell Lymphoma (DLBCL) of the Central Nervous System (CNS)
NCT05253118 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Systemic Therapies in the Treatment of Cutaneous T-cell Lymphoma
NCT06588868 ·Status: RECRUITING